Compare Amgen, Inc. (AMGN) vs Booking Holdings Inc (BKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Booking Holdings Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Booking Holdings Inc trades at $178.64 (market cap $138.23B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BKNG | |
|---|---|---|
Market Cap | $196.12B | $138.23B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $231.02 |
52-Week Low | $271.18 | $154.13 |
Enterprise Value | $241.41B | $141.15B |
Dividend Yield | 2.77% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Booking Holdings (BKNG) trades at $178.39, up 1.64% with mixed technical signals showing bearish overall momentum but bullish moving averages. The company maintains strong fundamentals with $26.92B revenue and 22.23% net margin in 2025, though Q2 2026 earnings remain pending. Recent news highlights AI integration efforts and travel demand resilience despite geopolitical concerns.
BKNG presents a compelling valuation case with analyst consensus target of $222.81 (25% upside) and no sell ratings. Key risks include AI disruption fears and Middle East tensions, but the company's dominant OTA position and robust cash flow generation support long-term growth prospects in the travel recovery cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →
